Market Overview

The Bull Thesis For Merck Is Evaporating

Share:
The Bull Thesis For Merck Is Evaporating
Related MRK
Merck Revisits Low Of Move And Rebounds
Pharma ETFs Down Post Q3 Earnings
Report: UPS license lets it get into pharma supply chain (Seeking Alpha)

The bullish case for Merck & Co., Inc. (NYSE: MRK) has been "derailed" after the company signaled to investors last week a longer-than-expected delay in a key lung cancer trial for its Keytruda therapy. Morgan Stanley's David Risinger downgrades Merck's stock rating from Overweight to Equal-Weight with a price target slashed from $69 to $56.

Many investors were working on the assumption that Merck's first-line lung cancer trial called Keynote 189 would see success in early 2018, the analyst wrote. However, the company guided to a new primary completion date for February 2019 with no clarity on any interim look timing although any interim look in 2018 will likely be successful.

On top of that, the company also pulled its first-line Keytruda chemo combo lung cancer application in Europe.

In the meantime, Merck's competition could win the race to report first-line lung cancer phase 3 results first, the analyst also wrote. Specifically, Bristol-Myers Squibb Co (NYSE: BMY) is expected to report two segments of its CheckMate-227 in the first half of 2018. Roche Holding Ltd. (ADR) (OTCM: RHHBY) is also expected to report first-line lung cancer trial results in the first half of 2018 from its IMpower 150.

Finally, Merck's Keytruda update prompted the analyst to make the following revisions to his estimates:

  • 2018 EPS lowered from $4.04 to $4.00.
  • 2019 EPS lowered from $4.34 to $4.17.
  • 2020 EPS lowered from $4.80 to $4.54.
  • Long-term EPS compounded annual growth rate from 6.7 percent to 5.4 percent.

At time of publication, shares of Merck were down 4.94 percent at $55.40.

Related Links:

5 Biggest Price Target Changes For Monday

Healthcare ETFs Set To Soar As Q3 Earnings Unfold

Latest Ratings for MRK

DateFirmActionFromTo
Oct 2017BMO CapitalMaintainsOutperform
Oct 2017JefferiesUpgradesUnderperformHold
Oct 2017UBSMaintainsBuy

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Downgrades Price Target FDA Analyst Ratings Movers Best of Benzinga

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!

Partner Center